Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Lymphoma

Free Subscription Articles published in Haematologica Retrieve available abstracts of 155 articles: HTML format

Single Articles

October 2025
1. MARR KC, Tang T, Simkin J, Kim J, et al
   Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience.
   Haematologica. 2025 Oct 9. doi: 10.3324/haematol.2025.288058.
   PubMed     Abstract available
   
   
   
2. SENTHIL H, Streilein S, Whiteside T, Minuk L, et al
   Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.
   Haematologica. 2025 Oct 9. doi: 10.3324/haematol.2025.288780.
   PubMed     Abstract available
   
   
   
3. YANG J, Hayden AR, Villa D, Jiang A, et al
   Utility of the Central Nervous System International Prognostic Index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy.
   Haematologica. 2025 Oct 2. doi: 10.3324/haematol.2025.288699.
   PubMed     Abstract available
   
   
   September 2025
4. CHUNG E, Wang L, Wellard C, Barraclough A, et al
   Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.
   Haematologica. 2025 Sep 25. doi: 10.3324/haematol.2025.287919.
   PubMed     Abstract available
   
   
   
5. SANTORO A, Improta CM, Sarina B, Mannina D, et al
   Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphoma.
   Haematologica. 2025 Sep 18. doi: 10.3324/haematol.2025.287672.
   PubMed     Abstract available
   
   
   August 2025
6. MOLLA R, Bantilan K, Berman E, Caron P, et al
   Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma.
   Haematologica. 2025 Aug 7. doi: 10.3324/haematol.2024.287165.
   PubMed     Abstract available
   
   
   July 2025
7. GHIONE P, Zinzani PL, Brown JR
   Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
   Haematologica. 2025 Jul 24. doi: 10.3324/haematol.2025.288114.
   PubMed     Abstract available
   
   
   
8. MOSKOWITZ AJ
   Fit, unfit, or frail? Now easier to tell for Hodgkin lymphoma.
   Haematologica. 2025 Jul 17. doi: 10.3324/haematol.2025.288033.
   PubMed     Abstract available
   
   
   
9. IACCARINO I, Beder T, Reinke S, Borchmann P, et al
   Long non-coding RNA LINC00926 is a biomarker for naive B-cells with prognostic value in advanced stage classic Hodgkin Lymphoma.
   Haematologica. 2025 Jul 17. doi: 10.3324/haematol.2025.287524.
   PubMed     Abstract available
   
   
   
10. ALHOMOUD M, Ibrahim R, Demetres M, Rejeski K, et al
    Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.
    Haematologica. 2025 Jul 10. doi: 10.3324/haematol.2025.287547.
    PubMed     Abstract available
    
    
    
11. SHOUSE G, Chen C, Muir A, Popplewell L, et al
    Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.
    Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2024.286945.
    PubMed     Abstract available
    
    
    
12. DANILOV AV, Li H, Shadman M, Rimsza L, et al
    Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial.
    Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2025.288057.
    PubMed     Abstract available
    
    
    
13. DOGLIOTTI I, Federico M
    BTKi +humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?
    Haematologica. 2025 Jul 3. doi: 10.3324/haematol.2025.288196.
    PubMed     Abstract available
    
    
    June 2025
14. ATALLAH-YUNES SA, Rees MJ, Habermann TM, Wang Y, et al
    Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single institution retrospective study of 66 patients.
    Haematologica. 2025 Jun 19. doi: 10.3324/haematol.2025.288145.
    PubMed     Abstract available
    
    
    
15. SCHMIDT C, Scheubeck G, Jurinovic V, Sokler M, et al
    Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.
    Haematologica. 2025 Jun 12. doi: 10.3324/haematol.2024.287162.
    PubMed     Abstract available
    
    
    
16. LIA K, Jorgensen RRK, Wikman P, Wold BL, et al
    Response to Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma.
    Haematologica. 2025 Jun 12. doi: 10.3324/haematol.2025.288284.
    PubMed     Abstract available
    
    
    
17. XAVIER AC, Liao Y, Cairo MS
    Persistent Epstein-Barr virus viremia in NK-/T-cell lymphoma: bad boys for life!
    Haematologica. 2025 Jun 5. doi: 10.3324/haematol.2025.287922.
    PubMed     Abstract available
    
    
    
18. HUANG K
    When 'simplified' may be oversimplified: reassessing frailty scoring in elderly Hodgkin lymphoma. Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma.
    Haematologica. 2025 Jun 5. doi: 10.3324/haematol.2025.288186.
    PubMed     Abstract available
    
    
    
19. AUTIO M, Bruck O, Pollari M, Karjalainen-Lindsberg ML, et al
    Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas.
    Haematologica. 2025;110:1339-1350.
    PubMed     Abstract available
    
    
    May 2025
20. MAGNI M, Jonnalagadda S, Bonifazi F, Bonafe M, et al
    CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.
    Haematologica. 2025 May 29. doi: 10.3324/haematol.2025.287528.
    PubMed     Abstract available
    
    
    
21. DE GROOT FA, Stedema FG, Kret EJ, De Haan LM, et al
    MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.
    Haematologica. 2025 May 29. doi: 10.3324/haematol.2025.287485.
    PubMed     Abstract available
    
    
    
22. ARDISSINO G, Angelillo P, Mancuso MC, Griffini S, et al
    Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab.
    Haematologica. 2025 May 15. doi: 10.3324/haematol.2025.287532.
    PubMed     Abstract available
    
    
    
23. BRISOU G, Paillassa J, Bernard S, Tournilhac O, et al
    Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study.
    Haematologica. 2025 May 15. doi: 10.3324/haematol.2024.287141.
    PubMed     Abstract available
    
    
    
24. EERTINK JJ, Heymans MW, Wiegers SE, Bes AL, et al
    Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response.
    Haematologica. 2025 May 15. doi: 10.3324/haematol.2024.287241.
    PubMed     Abstract available
    
    
    April 2025
25. SAITO M, Sato T, Hasegawa H, Tanabe K, et al
    Clonality analysis of HTLV-1-infected cells enhances prognostic precision in smoldering adult T-cell leukemia/lymphoma.
    Haematologica. 2025 Apr 30. doi: 10.3324/haematol.2025.287521.
    PubMed     Abstract available
    
    
    
26. LIA K, Jorgensen RRK, Wikman P, Wold BL, et al
    A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma.
    Haematologica. 2025 Apr 24. doi: 10.3324/haematol.2025.287509.
    PubMed     Abstract available
    
    
    
27. LI M, Zhang Y, Zong L, Zhang M, et al
    An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment.
    Haematologica. 2025 Apr 10. doi: 10.3324/haematol.2024.286923.
    PubMed     Abstract available
    
    
    
28. KIM TM, Lakhani NJ, Soumerai J, Kamdar M, et al
    Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study.
    Haematologica. 2025 Apr 10. doi: 10.3324/haematol.2024.286208.
    PubMed     Abstract available
    
    
    
29. ZHONG H, Cheng S, Xiong J, Chen J, et al
    Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.
    Haematologica. 2025 Apr 10. doi: 10.3324/haematol.2025.287513.
    PubMed     Abstract available
    
    
    
30. IANNITTO E, Ferrero S, Bommier C, Drandi D, et al
    Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
    Haematologica. 2025;110:1048-1049.
    PubMed    
    
    
    
31. JACQUEMIN G, Granci V, Gallouet AS, Lalaoui N, et al
    Erratum to: Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.
    Haematologica. 2025;110:1047.
    PubMed    
    
    
    March 2025
32. IGLESIAS R, Diaz E, Fernandez S, Miguelez M, et al
    Clonal hematopoiesis is common in bone marrow of patients with classical Hodgkin lymphoma.
    Haematologica. 2025 Mar 20. doi: 10.3324/haematol.2024.286579.
    PubMed     Abstract available
    
    
    
33. PORTUGUESE AJ, Huang JJ, Jeon Y, Taheri M, et al
    Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up.
    Haematologica. 2025 Mar 13. doi: 10.3324/haematol.2024.287010.
    PubMed     Abstract available
    
    
    
34. YAN M, Sethi S, Kumar J, Kumar A, et al
    Leukemic presentation in nodal mantle cell lymphoma is characterized by frequent SOX11 negativity, a poor risk genomic landscape including higher TP53 alterations, and worse overall survival.
    Haematologica. 2025 Mar 13. doi: 10.3324/haematol.2024.287108.
    PubMed     Abstract available
    
    
    
35. BOARDMAN AP, Gutgarts V, Flynn J, Devlin SM, et al
    Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy.
    Haematologica. 2025;110:651-664.
    PubMed     Abstract available
    
    
    
36. GHOSH N, Sehgal A, Liu FF, Kostic A, et al
    Comparative efficacy of lisocabtagene maraleucel in the PILOT study versus second-line chemotherapy regimens in the real world.
    Haematologica. 2025;110:693-705.
    PubMed     Abstract available
    
    
    February 2025
37. ALVEY EN, Yap KL, Rathbun P, Fitzpatrick C, et al
    B-cell lymphoblastic leukemia/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.
    Haematologica. 2025 Feb 27. doi: 10.3324/haematol.2024.286626.
    PubMed     Abstract available
    
    
    
38. EL DAKER S, Qualls D, Derkach A, Beqaj S, et al
    Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment.
    Haematologica. 2025 Feb 6. doi: 10.3324/haematol.2024.286383.
    PubMed     Abstract available
    
    
    
39. MINSON AG, Dickinson MJ
    New bispecific antibodies in diffuse large B-cell lymphoma.
    Haematologica. 2025 Feb 6. doi: 10.3324/haematol.2024.285343.
    PubMed     Abstract available
    
    
    
40. WILLSCHER E, Schultheiss C, Paschold L, Lea Schumann F, et al
    T-cell receptor architecture and clonal tiding provide insight into the transformation trajectory of peripheral T-cell lymphomas.
    Haematologica. 2025;110:457-469.
    PubMed     Abstract available
    
    
    January 2025
41. DOUGLAS G, Nicholls KM, Paul E, Loh Z, et al
    Opportunistic bone density assessment using pre-treatment [18F]FDG-PET/CT identifies fracture risk in lymphoma patients undergoing corticosteroid-containing chemotherapy.
    Haematologica. 2025 Jan 23. doi: 10.3324/haematol.2024.286618.
    PubMed     Abstract available
    
    
    
42. WENDLER J, Lewis RI, Kutilina A, Knott M, et al
    Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma.
    Haematologica. 2025 Jan 23. doi: 10.3324/haematol.2024.286347.
    PubMed     Abstract available
    
    
    
43. HUGHES AD, Polonen P, Teachey DT
    Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.
    Haematologica. 2025 Jan 9. doi: 10.3324/haematol.2024.285643.
    PubMed     Abstract available
    
    
    
44. SHAH NN, Wang M, Roeker LE, Patel K, et al
    Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
    Haematologica. 2025;110:92-102.
    PubMed     Abstract available
    
    
    
45. STEPHAN P, Perrot J, Voisin A, Barbery M, et al
    Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets.
    Haematologica. 2025;110:129-141.
    PubMed     Abstract available
    
    
    December 2024
46. SOSCIA R, Assanto GM, Starza ID, Moia R, et al
    Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma.
    Haematologica. 2024 Dec 19. doi: 10.3324/haematol.2024.286331.
    PubMed     Abstract available
    
    
    
47. DE MATTEIS S, Del Coco L, De Castro F, Giudetti AM, et al
    Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome.
    Haematologica. 2024 Dec 19. doi: 10.3324/haematol.2024.285154.
    PubMed     Abstract available
    
    
    
48. BIEDERMANN A, Patra-Kneuer M, Mougiakakos D, Buttner-Herold M, et al
    Blockade of the CD47/SIRPalpha checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.
    Haematologica. 2024;109:3928-3940.
    PubMed     Abstract available
    
    
    November 2024
49. NI V, Nasta SD, Barta SK, Schuster SJ, et al
    Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP.
    Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.286560.
    PubMed     Abstract available
    
    
    
50. FALCHI L, Hutchings M, Carlo-Stella C, Morschhauser F, et al
    Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma.
    Haematologica. 2024 Nov 28. doi: 10.3324/haematol.2024.286257.
    PubMed     Abstract available
    
    
    
51. ZELIKSON V, Gurumurthi A, Sawalha Y, Annunzio K, et al
    Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.
    Haematologica. 2024 Nov 14:0. doi: 10.3324/haematol.2024.285977.
    PubMed     Abstract available
    
    
    
52. LEMONNIER F, Philippe G
    In T-follicular helper lymphomas, 'one lymphoma can hide another': beginning to explain.
    Haematologica. 2024 Nov 14. doi: 10.3324/haematol.2024.286173.
    PubMed     Abstract available
    
    
    
53. GRAINGER BT, Cheah CY
    "The End of the Golden Weather": therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors.
    Haematologica. 2024 Nov 14. doi: 10.3324/haematol.2024.286205.
    PubMed     Abstract available
    
    
    
54. BARON M, Labreche K, Veyri M, Desire N, et al
    Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments.
    Haematologica. 2024;109:3615-3630.
    PubMed     Abstract available
    
    
    October 2024
55. VALCARCEL B, Schonfeld SJ, Shiels MS, Castillo JJ, et al
    Survival outcomes in diffuse large B-cell lymphoma patients with and without HIV in the United States from 2001 to 2016: a population-based analysis.
    Haematologica. 2024 Oct 31. doi: 10.3324/haematol.2024.286343.
    PubMed     Abstract available
    
    
    
56. NIZAMUDDIN IA, Bartlett NL
    Bispecific antibodies in follicular lymphoma.
    Haematologica. 2024 Oct 31. doi: 10.3324/haematol.2024.285245.
    PubMed     Abstract available
    
    
    
57. BRIEGHEL C, Petersen SL, Brown PN, Niemann CU, et al
    Frequency of secondary T-cell lymphoma in chimeric antigen receptor Tcell naive B-cell lymphoid-lineage cancers is higher than that reported on chimeric antigen receptor T-cell therapy.
    Haematologica. 2024 Oct 17. doi: 10.3324/haematol.2024.286002.
    PubMed     Abstract available
    
    
    
58. ATALLAH-YUNES SA, Rees MJ, Witzig TE, Habermann TM, et al
    CODOX-M/IVAC-R versus DA-EPOCH-R in double hit/triple hit lymphoma patients aged 60 years or under.
    Haematologica. 2024 Oct 10. doi: 10.3324/haematol.2024.286168.
    PubMed     Abstract available
    
    
    
59. DOGAN A, Roshal M
    Challenges in defining the immune microenvironment in T-cell lymphoma.
    Haematologica. 2024 Oct 10. doi: 10.3324/haematol.2024.285836.
    PubMed     Abstract available
    
    
    
60. BAGGIO D, Cwynarski K
    Thiotepa-based autograft for primary central nervous system lymphoma.
    Haematologica. 2024;109:3083-3084.
    PubMed    
    
    
    
61. VALCARCEL B, Schonfeld SJ, Jackson SS, Dores GM, et al
    Changes in sex-specific incidence of lymphoid neoplasms across the lifespan.
    Haematologica. 2024;109:3408-3413.
    PubMed    
    
    
    
62. TARANTELLI C, Wald D, Munz N, Spriano F, et al
    Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.
    Haematologica. 2024;109:3314-3326.
    PubMed     Abstract available
    
    
    September 2024
63. GUAN X, Wang Y, Fang T, Wang J, et al
    Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large Bcell lymphomas and regulates the pro-tumor microenvironment.
    Haematologica. 2024 Sep 26. doi: 10.3324/haematol.2024.285304.
    PubMed     Abstract available
    
    
    
64. CROCHET G, Houot R
    Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma": chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies.
    Haematologica. 2024 Sep 19. doi: 10.3324/haematol.2024.286353.
    PubMed     Abstract available
    
    
    
65. MERCADAL S, Ahn KW, Allbee-Johnson M, Ganguly S, et al
    Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy.
    Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285613.
    PubMed    
    
    
    
66. LIN N, Sun X, Zhou H, Zou L, et al
    Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial.
    Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.284973.
    PubMed     Abstract available
    
    
    
67. CASSANELLO G, Drill E, Rivas-Delgado A, Okwali M, et al
    Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.
    Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285600.
    PubMed     Abstract available
    
    
    
68. PHILLIPS T, Wang M, Robak T, Gallinson D, et al
    Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial.
    Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2023.284896.
    PubMed     Abstract available
    
    
    
69. SALVARIS RT, Allanson BM, Collins G, Cheah C, et al
    Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment.
    Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.285903.
    PubMed     Abstract available
    
    
    
70. URAK R, Pahlavanneshan S, Gittins B, Nakamura R, et al
    Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells.
    Haematologica. 2024;109:3053-3058.
    PubMed    
    
    
    
71. ALENCAR AJ, Alderuccio JP
    Not all central nervous system lymphomas are created equal.
    Haematologica. 2024;109:2769-2771.
    PubMed    
    
    
    August 2024
72. PILERI SA
    Entities versus diseases: Myers et al. propose distinct aspects of adult T-cell lymphoma/leukemia.
    Haematologica. 2024 Aug 29. doi: 10.3324/haematol.2024.286174.
    PubMed     Abstract available
    
    
    
73. HUANG D, Li F, Lin S, Xia J, et al
    A novel prognostic nomogram based on imaging and molecular parameters for newly diagnosed extranodal natural killer/T-cell lymphoma patients.
    Haematologica. 2024 Aug 15:0. doi: 10.3324/haematol.2024.285362.
    PubMed     Abstract available
    
    
    
74. RAVIKRISHNAN J, Diaz-Rohena DY, Muhowski E, Mo X, et al
    LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.
    Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2023.284353.
    PubMed     Abstract available
    
    
    
75. HILTON LK
    A nu mouse model of diffuse large B-cell lymphoma in constitutional Atm loss.
    Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2024.285973.
    PubMed     Abstract available
    
    
    
76. MYERS CS, Williams E, Cornejo CB, Pongas G, et al
    Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations.
    Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2024.285233.
    PubMed     Abstract available
    
    
    
77. EPSTEIN-PETERSON ZD, Drill E, Aypar U, Batlevi CL, et al
    Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
    Haematologica. 2024;109:2749-2752.
    PubMed    
    
    
    
78. MOSKOWITZ AJ
    Combination chemotherapy for Hodgkin lymphoma.
    Haematologica. 2024;109:2383-2384.
    PubMed    
    
    
    July 2024
79. HOLST JM, Pedersen MB, Enemark MB, Hansen MC, et al
    Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphoma.
    Haematologica. 2024 Jul 25. doi: 10.3324/haematol.2023.283798.
    PubMed     Abstract available
    
    
    
80. MELODY M, Gordon LI
    Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma.
    Haematologica. 2024 Jul 18. doi: 10.3324/haematol.2024.285255.
    PubMed     Abstract available
    
    
    
81. GARGANO G, Vegliante MC, Esposito F, Pappagallo SA, et al
    A targeted gene signature stratifying mediastinal gray zone lymphoma into classical HL-like or PMBL-like subtypes.
    Haematologica. 2024 Jul 18. doi: 10.3324/haematol.2024.285266.
    PubMed     Abstract available
    
    
    
82. OTHMAN T, Frankel P, Allen P, Popplewell LL, et al
    Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.
    Haematologica. 2024 Jul 18. doi: 10.3324/haematol.2024.285185.
    PubMed     Abstract available
    
    
    
83. WANG L
    Have we truly uncovered the key to primary vitreoretinal lymphoma's pathway to the central nervous system?
    Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.286056.
    PubMed     Abstract available
    
    
    
84. SERNA A, Navarro V, Iacoboni G, Lopez L, et al
    Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes.
    Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.285219.
    PubMed     Abstract available
    
    
    
85. DOURTHE ME, Auperin A, Rigaud C, Barbati M, et al
    Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with FAB/LMB-based chemotherapy regimen with rituximab.
    Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.285403.
    PubMed     Abstract available
    
    
    
86. DE JONGE AV, Bruins WSC, Duetz C, Korst CLBM, et al
    Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T-cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.
    Haematologica. 2024 Jul 4. doi: 10.3324/haematol.2024.285170.
    PubMed     Abstract available
    
    
    
87. SALVINO MA, Domingo-Domenech E, Sureda A
    The importance of secondary cancer screening programs in Hodgkin lymphoma survivors.
    Haematologica. 2024 Jul 4. doi: 10.3324/haematol.2023.284609.
    PubMed     Abstract available
    
    
    
88. AL-SAWAF O
    High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies.
    Haematologica. 2024;109:2035-2037.
    PubMed    
    
    
    
89. SONG Y, Cao J, Zhang Q, Li C, et al
    Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
    Haematologica. 2024;109:2165-2176.
    PubMed     Abstract available
    
    
    June 2024
90. KASPRZYK ME, Sura W, Podralska M, Kazimierska M, et al
    Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen.
    Haematologica. 2024 Jun 27. doi: 10.3324/haematol.2023.284672.
    PubMed     Abstract available
    
    
    
91. HERBAUX C, Bret C, Bachy E, Bories P, et al
    Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.
    Haematologica. 2024 Jun 20. doi: 10.3324/haematol.2023.284786.
    PubMed     Abstract available
    
    
    
92. BENJAMINI O, Fried S, Shouval R, Flynn JR, et al
    Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma.
    Haematologica. 2024 Jun 20. doi: 10.3324/haematol.2023.284664.
    PubMed     Abstract available
    
    
    
93. KAPHAN E, Bettega F, Vallet N, Fegueux N, et al
    PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire.
    Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2024.284968.
    PubMed     Abstract available
    
    
    
94. CHENG J, Xi L, Jang Y, Kim J, et al
    An investigation of germline variants of HAVCR2 in subcutaneous panniculitis-like T-cell lymphoma and related lesions in a North American population.
    Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2023.284738.
    PubMed     Abstract available
    
    
    
95. IZUMIYAMA K, Inao T, Goto H, Harada S, et al
    Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.
    Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2023.284841.
    PubMed     Abstract available
    
    
    
96. DAVIES N, Francis T, Oldreive C, Azam M, et al
    Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma.
    Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.284404.
    PubMed     Abstract available
    
    
    
97. YOSHIFUJI K, Sadato D, Toya T, Motomura Y, et al
    Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma.
    Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.284953.
    PubMed     Abstract available
    
    
    
98. RAI S, Kim WS, Ando K, Choi I, et al
    Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.
    Haematologica. 2024 Jun 6. doi: 10.3324/haematol.2023.283992.
    PubMed     Abstract available
    
    
    May 2024
99. DANILOV AV, Flinn IW, Davids MS, Gregory B, et al
    The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival.
    Haematologica. 2024 May 30. doi: 10.3324/haematol.2024.285043.
    PubMed     Abstract available
    
    
    
100. GHIONE P, Salles G
     Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?
     Haematologica. 2024 May 30. doi: 10.3324/haematol.2022.282362.
     PubMed     Abstract available
     
     
     
101. YADIGAROGLU K, Scharf S, Gretser S, Schafer H, et al
     Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma.
     Haematologica. 2024 May 23. doi: 10.3324/haematol.2023.284512.
     PubMed     Abstract available
     
     
     
102. ELICE F, Sommaggio R, Cappuzzello E, Riva M, et al
     A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report.
     Haematologica. 2024 May 9. doi: 10.3324/haematol.2023.284881.
     PubMed     Abstract available
     
     
     
103. RENAUD L, Wencel J, Pages A, Al Jijakli A, et al
     Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.
     Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.284689.
     PubMed     Abstract available
     
     
     April 2024
104. LINK BK
     Follicular lymphoma treatment decisions: put GELF on the shelf?
     Haematologica. 2024 Apr 24. doi: 10.3324/haematol.2024.285286.
     PubMed     Abstract available
     
     
     
105. CAIRO MS
     TP3 binding domain mutations are bad news in Burkitt lymphoma.
     Haematologica. 2024 Apr 18. doi: 10.3324/haematol.2024.285213.
     PubMed     Abstract available
     
     
     
106. BOURLON C, Roddie C, Menne T, Norman J, et al
     Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
     Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285010.
     PubMed     Abstract available
     
     
     
107. IKEDA D, Oura M, Uehara A, Tabata R, et al
     Prognostic relevance of tumor-infiltrating CD4(+) cells and total metabolic tumor volume-based risk stratification in diffuse large B-cell lymphoma.
     Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285038.
     PubMed     Abstract available
     
     
     March 2024
108. BI C, Huang Y, Ali R, Wang F, et al
     MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications.
     Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2023.283811.
     PubMed     Abstract available
     
     
     
109. PULCZYNSKI EJ, Simonsen MR, Kuittinen O, Fagerli UM, et al
     Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up.
     Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.285207.
     PubMed     Abstract available
     
     
     
110. WIGHT J, Blombery P, Lickiss J, Burgess M, et al
     Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance.
     Haematologica. 2024 Mar 21. doi: 10.3324/haematol.2023.284600.
     PubMed     Abstract available
     
     
     
111. IANNITTO E, Ferrero S, Bommier C, Drandi D, et al
     Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
     Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109.
     PubMed     Abstract available
     
     
     
112. ZHU ML, Drill E, Joffe E, Salles G, et al
     Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center.
     Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284565.
     PubMed     Abstract available
     
     
     
113. TOLLEY ER, Lewinter C, Pedersen LM, Nielsen TH, et al
     Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis.
     Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284281.
     PubMed     Abstract available
     
     
     
114. BARRACLOUGH A, Agrawal S, Talaulikar D, Chong G, et al
     Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study.
     Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284538.
     PubMed     Abstract available
     
     
     February 2024
115. DURAND R, Bellanger C, Kervoelen C, Tessoulin B, et al
     Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma.
     Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284345.
     PubMed     Abstract available
     
     
     
116. MARTIRE G, Lovisa F, Carraro E, Rizzato D, et al
     TP53 DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification.
     Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284868.
     PubMed     Abstract available
     
     
     
117. STATHIS A, Pirosa MC, Orsucci L, Feugier P, et al
     IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
     Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283918.
     PubMed     Abstract available
     
     
     
118. YUAN X, Xie Y, Xu N, Liu H, et al
     Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.
     Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284834.
     PubMed     Abstract available
     
     
     
119. SAVAGE KJ, De Leval L
     Erratum to: Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization.
     Haematologica. 2024;109:693-694.
     PubMed    
     
     
     
120. KUPPERS R
     Distinct t(14;19) translocation patterns in atypical chronic lymphocytic leukemia and marginal zone lymphomas.
     Haematologica. 2024;109:376-378.
     PubMed    
     
     
     
121. CARBO-MEIX A, Guijarro F, Wang L, Grau M, et al
     BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases.
     Haematologica. 2024;109:493-508.
     PubMed     Abstract available
     
     
     January 2024
122. DESMARES A, Bouzy S, Thonier F, Goustille J, et al
     Hepatosplenic T-cell lymphoma displays an original oyster-shell cytological pattern and a distinct genomic profile from that of gamma-delta T-cell large granular lymphocytic leukemia.
     Haematologica. 2024 Jan 25. doi: 10.3324/haematol.2023.283856.
     PubMed     Abstract available
     
     
     
123. TUN AM, Wang Y, Maliske S, Micallef I, et al
     Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.
     Haematologica. 2024 Jan 18. doi: 10.3324/haematol.2023.284704.
     PubMed     Abstract available
     
     
     
124. SAVAGE KJ, Slack GW
     Erratum to: DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome.
     Haematologica. 2024;109:365.
     PubMed    
     
     
     December 2023
125. SAVAGE KJ, De Leval L
     Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization.
     Haematologica. 2023;108:3204-3210.
     PubMed    
     
     
     
126. LEWIS NE, Zhou T, Dogan A
     Biology and genetics of extranodal mature T-cell and NKcell lymphomas and lymphoproliferative disorders.
     Haematologica. 2023;108:3261-3277.
     PubMed     Abstract available
     
     
     
127. STUVER R, Epstein-Peterson ZD, Horwitz SM
     Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas.
     Haematologica. 2023;108:3244-3260.
     PubMed     Abstract available
     
     
     
128. BISIG B, Savage KJ, De Leval L
     Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.
     Haematologica. 2023;108:3227-3243.
     PubMed     Abstract available
     
     
     
129. NGU HS, Savage KJ
     Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
     Haematologica. 2023;108:3211-3226.
     PubMed     Abstract available
     
     
     
130. LACAN C, Caron J, Tarantino N, Fouquet B, et al
     CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes.
     Haematologica. 2023;108:3485-3490.
     PubMed    
     
     
     
131. ZHANG L, Zhu X, Qu W, Lu Y, et al
     Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PCM1::JAK2 with erythroblastic sarcoma: a case report and literature review.
     Haematologica. 2023;108:3506-3510.
     PubMed    
     
     
     November 2023
132. JALLOUK AP, Kui N, Sun R, Westin JR, et al
     Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
     Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.284453.
     PubMed     Abstract available
     
     
     
133. MAURER MJ, Casulo C, Larson MC, Habermann TM, et al
     Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
     Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283737.
     PubMed     Abstract available
     
     
     
134. CARRAS S, Torroja A, Emadali A, Montaut E, et al
     Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
     Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283724.
     PubMed     Abstract available
     
     
     
135. BROADBENT R, Crosbie P, Armitage CJ, Taylor B, et al
     Pilot study of lung cancer screening for survivors of Hodgkin lymphoma.
     Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.283287.
     PubMed     Abstract available
     
     
     
136. HOFFMANN MS
     Routine consolidation of early stage primary bone lymphoma with radiation therapy does not improve outcomes.
     Haematologica. 2023 Nov 16. doi: 10.3324/haematol.2023.284303.
     PubMed     Abstract available
     
     
     
137. DE CONINCK S, De Smedt R, Lintermans B, Reunes L, et al
     Targeting hyperactive platelet-derived growth factor receptor-beta signaling in T-cell acute lymphoblastic leukemia and lymphoma.
     Haematologica. 2023 Nov 9. doi: 10.3324/haematol.2023.283981.
     PubMed     Abstract available
     
     
     
138. MAYR F, Kruse V, Fuhrmann DC, Wolf S, et al
     SH2 domain-containing inositol 5-phosphatases support the survival of Burkitt lymphoma cells by promoting energy metabolism.
     Haematologica. 2023 Nov 2. doi: 10.3324/haematol.2023.283663.
     PubMed     Abstract available
     
     
     
139. MAURER MJ
     The International Prognostic Index in aggressive B-cell lymphoma.
     Haematologica. 2023;108:2874-2879.
     PubMed    
     
     
     
140. LEIVONEN SK, Friman T, Autio M, Vaittinen S, et al
     Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas.
     Haematologica. 2023;108:3044-3057.
     PubMed     Abstract available
     
     
     October 2023
141. LIA K, Jorgensen RRK, L Wold B, Fluge O, et al
     Overall survival and causes of death in elderly patients with Hodgkin lymphoma: a Norwegian population-based case-control study.
     Haematologica. 2023 Oct 26. doi: 10.3324/haematol.2023.283721.
     PubMed     Abstract available
     
     
     
142. KUMAR A
     MYC overexpression: adding another piece to the puzzle of high-risk mantle cell lymphoma.
     Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.284105.
     PubMed     Abstract available
     
     
     
143. REZAZADEH A, Szabo A, Khurana A, Inwards DJ, et al
     Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
     Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283210.
     PubMed     Abstract available
     
     
     
144. SONG YQ, Zhang HL, Huang HQ, Zhang QY, et al
     Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.
     Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283802.
     PubMed     Abstract available
     
     
     
145. MEEUWES FO, Brink M, Plattel W, Van der Poel MWM, et al
     Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
     Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283174.
     PubMed     Abstract available
     
     
     
146. CROSSWELL HE, LaCasce AS, Bartlett NL, Straus DJ, et al
     Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
     Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283303.
     PubMed     Abstract available
     
     
     
147. KAWATA T, Shimizu T, Shindo T, Fujiwara K, et al
     Tucidinostat restores CCR4 expression in adult T-cell leukemia/lymphoma.
     Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.283266.
     PubMed     Abstract available
     
     
     
148. HO C, Smith SD
     More than a Lonca-shot: beating the odds in relapsed/refractory diffuse large B-cell lymphoma.
     Haematologica. 2023 Oct 5. doi: 10.3324/haematol.2023.284056.
     PubMed     Abstract available
     
     
     
149. PASTORCZAK A, Szmyd B, Braun M, Madzio J, et al
     Clinical and laboratory diversity of diffuse large B-cell lymphomas in children with Nijmegen breakage syndrome.
     Haematologica. 2023;108:2808-2813.
     PubMed    
     
     
     September 2023
150. KHANLARI M, Wang W, Liu YC, Wang L, et al
     Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical STIL::TAL1 fusion events.
     Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283585.
     PubMed     Abstract available
     
     
     
151. FLOWERS CR, Matasar MJ, Herrera AF, Hertzberg M, et al
     Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
     Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283557.
     PubMed     Abstract available
     
     
     
152. FEHNIGER TA, Watkins MP, Ezenwajiaku N, Wan F, et al
     A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
     Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2022.282246.
     PubMed     Abstract available
     
     
     
153. ROSCHEWSKI M, Hodson DJ
     Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
     Haematologica. 2023 Sep 14. doi: 10.3324/haematol.2021.278613.
     PubMed     Abstract available
     
     
     
154. FUKANO R, Iijima-Yamashita Y, Iwafuchi H, Nakazawa A, et al
     Prognostic value of minimal disseminated disease assessed using digital PCR for 3'ALK assays in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
     Haematologica. 2023 Sep 7. doi: 10.3324/haematol.2023.282812.
     PubMed     Abstract available
     
     
     
155. LUMINARI S
     Prognostic tools for older patients with diffuse large B-cell lymphoma: complex patients require complex solutions and a personal touch.
     Haematologica. 2023;108:2269-2270.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.